NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Thursday that its first quarter revenues rose 226 percent year over year, driven by a 150 percent increase in the number of completed Cologuard colon cancer tests.

For the three months ended March 31, the diagnostics company reported revenues of $48.4 million, up from $14.8 million a year earlier, and blowing away the analyst estimate of $37.3 million.

Exact completed 100,000 Cologuard tests during the quarter, with an average recognized revenue per test of $485.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.